![JCM | Free Full-Text | Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study JCM | Free Full-Text | Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study](https://www.mdpi.com/jcm/jcm-10-05311/article_deploy/html/images/jcm-10-05311-g001.png)
JCM | Free Full-Text | Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study
![Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation | Drug Delivery and Translational Research Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation | Drug Delivery and Translational Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13346-023-01372-1/MediaObjects/13346_2023_1372_Figa_HTML.png)
Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation | Drug Delivery and Translational Research
![Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab - ScienceDirect Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1542356522010059-fx1.jpg)
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab - ScienceDirect
![Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial | Scientific Reports Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-18387-7/MediaObjects/41598_2017_18387_Fig1_HTML.jpg)
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial | Scientific Reports
![Biosimilar strategy for infliximab by MedDrive™ includes the reference drug - Prime Therapeutics LLC Biosimilar strategy for infliximab by MedDrive™ includes the reference drug - Prime Therapeutics LLC](https://www.primetherapeutics.com/wp-content/uploads/2022/01/PA-PS-InfliximabFDA-approvals-2022.jpg)